Compare ENSC & SVRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENSC | SVRE |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.7M |
| IPO Year | 2017 | 2021 |
| Metric | ENSC | SVRE |
|---|---|---|
| Price | $0.43 | $3.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 21.4M | 68.6K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.24 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,066,650.00 | N/A |
| Revenue This Year | $55.01 | $1,793.31 |
| Revenue Next Year | $1,033.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.55 |
| 52 Week High | $2.75 | $6.30 |
| Indicator | ENSC | SVRE |
|---|---|---|
| Relative Strength Index (RSI) | 65.10 | 57.35 |
| Support Level | $0.27 | $3.25 |
| Resistance Level | $0.65 | $3.94 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 27.08 | 75.97 |
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.